Trials / Completed
CompletedNCT02445742
CML Treated With Bosutinib After Relapse
Single Nucleotide Polymorphism Association With Response and Toxic Effects in Patients With Ph+ CP-CML Treated With Bosutinib After Relapse to Previous Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- PETHEMA Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, open label, multicenter, phase II study evaluating correlation of SNPs with efficacy and toxicity in patients treated with Bosutinib. A total of 50 patients with previously treated Ph+ chronic phase CML will be included in the study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bosutinib | 500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2018-12-01
- Completion
- 2019-06-27
- First posted
- 2015-05-15
- Last updated
- 2020-04-29
Locations
13 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02445742. Inclusion in this directory is not an endorsement.